- Home
- DIBS vs CHRS Comparison
DIBS vs CHRS Comparison
Compare DIBS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIBS
- CHRS
- Stock Information
- Founded
- DIBS 2000
- CHRS 2010
- Country
- DIBS United States
- CHRS United States
- Employees
- DIBS N/A
- CHRS N/A
- Industry
- DIBS Catalog/Specialty Distribution
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DIBS Consumer Discretionary
- CHRS Health Care
- Exchange
- DIBS Nasdaq
- CHRS Nasdaq
- Market Cap
- DIBS 88.1M
- CHRS 102.0M
- IPO Year
- DIBS 2021
- CHRS 2014
- Fundamental
- Price
- DIBS $2.76
- CHRS $0.94
- Analyst Decision
- DIBS Hold
- CHRS Buy
- Analyst Count
- DIBS 1
- CHRS 3
- Target Price
- DIBS N/A
- CHRS $4.68
- AVG Volume (30 Days)
- DIBS 43.5K
- CHRS 1.4M
- Earning Date
- DIBS 08-06-2025
- CHRS 08-07-2025
- Dividend Yield
- DIBS N/A
- CHRS N/A
- EPS Growth
- DIBS N/A
- CHRS N/A
- EPS
- DIBS N/A
- CHRS N/A
- Revenue
- DIBS $88,740,000.00
- CHRS $272,251,000.00
- Revenue This Year
- DIBS $3.02
- CHRS N/A
- Revenue Next Year
- DIBS $6.51
- CHRS $99.43
- P/E Ratio
- DIBS N/A
- CHRS N/A
- Revenue Growth
- DIBS 4.93
- CHRS 19.87
- 52 Week Low
- DIBS $2.30
- CHRS $0.66
- 52 Week High
- DIBS $5.00
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- DIBS 52.17
- CHRS 53.76
- Support Level
- DIBS $2.64
- CHRS $0.88
- Resistance Level
- DIBS $2.78
- CHRS $1.15
- Average True Range (ATR)
- DIBS 0.12
- CHRS 0.08
- MACD
- DIBS -0.01
- CHRS 0.00
- Stochastic Oscillator
- DIBS 75.79
- CHRS 37.00
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.